Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Prenatal TNF Inhibitor Exposure Not Linked to Serious Infections

Anne Harding  |  

Offspring exposed to infliximab showed a trend toward increased risk of serious infections compared to infants exposed to other TNFi agents.

Acute bronchiolitis due to respiratory syncytial virus was the most common serious infection in all three groups, accounting for about one-third of all serious infections in each group. There were no cases of tuberculosis in exposed or unexposed RA offspring.

ADVERTISEMENT
SCROLL TO CONTINUE

Although the findings could not confirm an increased risk of TNFi drugs overall, Dr. Vinet notes, “we could not exclude a differential risk according to specific TNFi characteristics, with infliximab potentially resulting in a three-fold increase in the risk of serious infections compared with other TNFis.”

Reference

ADVERTISEMENT
SCROLL TO CONTINUE
  1. Vinet É, De Moura C, Pineau CA, et al. Serious infections in rheumatoid arthritis offspring exposed to tumour necrosis factor α inhibitors: Cohort study. Arthritis Rheumatol. 2018 May 17. doi: 10.1002/art.40536. [Epub ahead of print]

Related Articles

    TNFi Exposure in Utero

    Vinet et al. evaluated the risk of serious infections in children of women with RA exposed to TNFi’s in the gestational period compared with unexposed offspring of women with RA, as well as with children from the general population. Although the research did not demonstrate a marked excess risk for serious infections, the authors could not exclude a differential risk according to specific TNFi, with infliximab potentially resulting in a threefold increase in the risk of serious infections compared with other TNFi’s. More studies are needed…

    Rheumatology Drugs at a Glance, Part 3: Rheumatoid Arthritis

    Over the past few years, bio­similars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options, others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and small molecule inhibitor drugs…

    MicroOne / shutterstock.com

    Rheumatology Drugs at a Glance, Part 2: Psoriasis

    Over the past few years, bio­similars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug option; others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and other medications used to…

    kenary820 / shutterstock.com

    Rheumatology Drugs at a Glance, Part 1: Psoriatic Arthritis

    Over the past few years, biosimilars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options, others have few or only off-label options. This series, Rheumatology Drugs at a Glance, provides streamlined information on the administration of biologic, biosimilar and other medications used to…